Navigation Links
Gleevec Prevents Return of Intestinal Cancer, Study Confirms
Date:3/19/2009

Drug is shown to be most effective on larger tumors

THURSDAY, March 19 (HealthDay News) -- Taking Gleevec after surgery to remove a gastrointestinal stromal tumor improves tumor-free survival, a U.S. study has confirmed.

Gastrointestinal stromal tumors (GIST), the most common soft-tissue cancer of the intestinal tract, typically occur in the stomach or small intestine. About 3,000 to 4,000 cases are diagnosed in the United States each year. According to background information in the study, about 85 percent of these tumors have a protein that allows them to be inhibited by Gleevec, known as imatinib.

The finding stems from a phase 3 trial for the drug, which was approved last year by the U.S. Food and Drug Administration to treat people who've had surgery to remove a GIST. The drug already was approved for treating certain types of adult leukemia.

The trial included more than 700 people with a GIST at least 3 centimeters in size that tested positive for the protein. The participants were randomly selected to take either 400 milligrams of Gleevec or a placebo once a day for a year after surgery to remove their tumor.

After a median follow-up of almost 20 months, 8 percent of people in the Gleevec group and 20 percent of those in the placebo group had experienced tumor recurrence or had died. After a year, recurrence-free survival was 98 percent for those taking the drug and 83 percent for people taking the placebo.

Tumor size affected treatment success, the study found. Gleevec had the most effect on tumors that were 10 cm or larger, less effect on tumors between 6 and 10 cm, and the least effect on tumors between 3 and 6 cm, the study reported.

The most common serious side effects experienced by people taking the drug were dermatitis, abdominal pain and diarrhea.

Dr. Ronald DeMatteo, of Memorial Sloan-Kettering Cancer Center, and his fellow researchers said that their "findings will affect the management of patients with primary gastrointestinal stromal tumor and could have relevance to the adjuvant use of other molecular agents for cancer."

The study appears online and in an upcoming print issue of The Lancet.

Dr. Peter Hohenberger, of the University of Heidelberg, in Mannheim, Germany, said in an accompanying comment that more research is needed.

"There are so many unknowns that this trial might not be able to provide a definitive treatment decision," he wrote. "To refine the indication for adjuvant treatment remains the big task for future studies."

More information

The American Cancer Society has more about GIST.



-- Robert Preidt



SOURCE: The Lancet, news release, March 18, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
2. Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)
3. Cancer Drug Gleevec Could Fight Stroke
4. Cancer Drug Gleevec Linked to Muscle Damage
5. Protein predicts Gleevec resistance in gastrointestinal tumors
6. Gleevec Pushes Advanced Melanoma Into Remission
7. Gleevec May Disrupt Ovarian Function
8. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
9. Gleevec, the targeted cancer pill, delivers more good news to patients
10. Cell pathway on overdrive prevents cancer response to dietary restriction
11. New surgical implant tested at U-Iowa prevents total blindness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gleevec Prevents Return of Intestinal Cancer, Study Confirms
(Date:1/24/2017)... ... January 24, 2017 , ... “Speaking With God’s Voice”: ... God’s Voice” is the creation of published author, Louis A. Miraglia, a born-again believer, ... best to deliver God’s great, impactful Word. , “There is little doubt that ...
(Date:1/24/2017)... ... 24, 2017 , ... “Mysteries Revealed On Speaking In Tongues”: an engaging ... to all Christians. “Mysteries Revealed On Speaking In Tongues” is the creation of published ... talk show located in Michigan. , “We need to partner with Jesus and ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink is now ... Coffee Protein Drink Mix has become popular among health-conscious consumers who love coffee ...
(Date:1/24/2017)... Utah (PRWEB) , ... January 23, 2017 , ... The ... now) features a three-year outcome study on how outdoor behavioral healthcare (OBH) – also ... of distress and interpersonal difficulties while experiencing an increased sense of purpose both during ...
(Date:1/24/2017)... ... January 23, 2017 , ... Somnoware, a leading provider of ... centers to automatically connect and initialize all their devices with one click. This ... quickly installed on first use and then monitors device changes automatically. With this ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Jan. 23, 2017 The global peripheral I.V. ... and it is expected to grow at a CAGR ... segment accounted for larger share in the global market ... various end users, the hospital segment accounted for the ... year. The global peripheral I.V. catheter market is witnessing ...
(Date:1/23/2017)... DUBLIN , Jan. 23, 2017 Endo ... Federal Trade Commission (FTC) today filed a joint motion ... of California seeking the entry ... Stipulated Order resolves all disputes between the FTC and ... into in connection with its Opana® ER and Lidoderm® ...
(Date:1/23/2017)... YORK , Jan. 23, 2017 MouthWatch LLC ... Camera was ranked as the best intraoral camera on ... taking the #2 spot overall. The #1 product was the ... said the MouthWatch intraoral camera was "…incredibly popular because it ... the camera has a small sticker price, it doesn,t sacrifice ...
Breaking Medicine Technology: